EL7.AI
StocksMedium•25 March 2026•
1 min read

Shore Capital Reiterates 'Buy' Rating for GSK Following Favorable Court Ruling

Key Facts

1Shore Capital reiterated its 'buy' recommendation for GSK with a fair value target of 2,500p.
2Analysts noted the stock trades at 14x 2026 earnings, which is considered cheap relative to growth ambitions and peers.
3A recent court ruling has helped dissipate market concerns that were previously weighing on the stock.

Shore Capital has reaffirmed its "buy" recommendation for GSK PLC, setting a fair value target of 2,500p. The decision comes as analysts believe the pharmaceutical giant's current valuation remains attractive compared to its long-term growth prospects and industry peers. According to Dr. Sean Conroy, the stock is trading at approximately 14 times its projected 2026 earnings, which is considered undervalued in the current market context. A significant driver for this positive outlook is a recent court ruling that has effectively dissipated major legal uncertainties previously weighing on the company's stock performance. With these legal risks receding, the focus has shifted back to GSK's fundamental growth ambitions and strategic pipeline. Market sentiment remains supportive as the company continues to navigate its expansion with reduced litigation pressure.